Results 211 to 220 of about 99,788 (345)

Scrotal squamous cell carcinoma: Two HPV‐negative cases with probable UV‐ induced pathogenesis

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Daniel Craus   +7 more
wiley   +1 more source

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu   +13 more
wiley   +1 more source

Spatial clusters and temporal trends of cutaneous malignant melanoma mortality in Spain. [PDF]

open access: yesJ Int Med Res
Cayuela L   +3 more
europepmc   +1 more source

Primary Cutaneous Malignant Melanoma of the Breast: A Case Report

open access: diamond, 2019
Seyyed Adel Maleknia   +4 more
openalex   +2 more sources

HPV125‐induced generalized verrucosis

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven Niklas Burmann   +7 more
wiley   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel   +27 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy